Absci Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABSI research report →
Range $10 – $16
Price Chart
About the company
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process.
- CEO
- Sean McClain
- IPO
- 2021
- Employees
- 140
- HQ
- Vancouver, WA, US
Get TickerSpark's AI analysis on ABSI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.30B
- P/E
- -10.25
- PEG
- -0.77
- P/S
- 940.26
- P/B
- 6.36
- EV/EBITDA
- -12.09
- Div Yield
- 0.00%
- Gross Margin
- -2647.41%
- Op Margin
- -9155.35%
- Net Margin
- -8451.31%
- ROE
- -60.84%
- ROIC
- -61.05%
Latest fiscal year · YoY change
- Revenue
- $2.80M-38.2%
- Gross Profit
- $-8,942,000+84.6%
- Op Income
- $-124,718,000
- Net Income
- $-115,183,000-11.7%
- EPS
- $-0.84+10.6%
- OCF Growth
- -28.3%
- FCF Growth
- -29.2%
- 52W High
- $12.54
- 52W Low
- $2.24
- 50D MA
- $9.58
- 200D MA
- $6.95
- Beta
- 2.23
- RSI (14)
- 39
- Avg Volume
- 4.08M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Absci said Q3 progress on its lead ABS-201 hair-loss program is on track, with interim 13-week data due next month, while cash runway extends into the second half of 2028.· November 12, 2026
- ABS-201’s ongoing pattern hair loss trial is progressing as planned, with 13-week interim data expected next month and full 26-week proof-of-concept data early next year.
- Management said the trial is showing encouraging safety, pharmacokinetic and immunogenicity signals so far, and they believe the regimen may support 2 to 3 injections over 6 months.
- Absci is also moving toward a Phase 2 endometriosis trial in mid-2027, with the company positioning ABS-201 as a platform for multiple prolactin-receptor indications.
- The company added a first chief commercial officer as it builds direct-to-consumer commercial capabilities for future programs.
- Cash, cash equivalents and marketable securities were $173.7 million at September 30, 2026, and management said that should fund operations into the second half of 2028.
For the quarter ended September 30, 2026, research and development expense was $23.6 million versus $19.2 million in the prior-year period, and selling, general and administrative expense was $9.0 million versus $8.4 million a year ago. Cash, cash equivalents and marketable securities were $173.7 million at September 30, 2026, compared with $201.1 million as of June 30, 2020. Management said this cash position is sufficient to fund operating plans into the second half of 2028. No revenue, gross margin, or EPS figures were stated in the call. Forward-looking guidance was centered on ABS-201: 13-week interim PHL data next month, full 26-week POC data early next year, and Phase 2 endometriosis trial initiation in mid-2027.
Sean McClain framed the quarter as a setup period for multiple near-term catalysts, emphasizing the upcoming 13-week and 26-week ABS-201 readouts and the planned endometriosis program. His tone was upbeat and promotional, repeatedly highlighting ABS-201 as a “blueprint” asset and positioning the prolactin franchise as a broader platform for future indications. He also underscored the company’s move toward commercial infrastructure, including direct-to-consumer opportunities and the hiring of a chief commercial officer.
Zachariah Jonasson focused on capital allocation, saying Absci is prioritizing programs aimed at large unmet-need markets and evaluating each through a commercial lens, including DTC distribution potential. He said R&D was $23.6 million and SG&A was $9.0 million for the quarter, with the R&D increase driven mainly by external nonclinical and clinical work on ABS-201 and SG&A up mainly due to stock-based compensation. He reiterated that $173.7 million in cash, cash equivalents and marketable securities should support the current plan into the second half of 2028.
Analysts focused on how to interpret the upcoming 13-week data versus the more important 26-week readout, especially around total hair count, placebo response, and whether the interim readout could alter the trial. Management said the 13-week update is meant to show a directional biological signal and will not change the conduct of the study; they also said the key decision point for Phase 3 dosing will be the 26-week data. Questions also covered female cohort dosing, competitor hair-loss data, receptor occupancy and PK/PD; management said the female cohorts are exploratory open-label studies, that they are targeting at least 90% receptor occupancy, and that the current PK supports dosing every 2 to 3 months.
The bull case from the call is that ABS-201 appears to be advancing cleanly toward multiple near-term clinical milestones with encouraging early safety/PK signals. Management believes the drug’s long half-life, high receptor occupancy, and potential for durable hair growth could support a differentiated profile in both hair loss and endometriosis, while cash runway into 2028 gives the company time to execute.
The main risks are that all of the important efficacy readouts are still ahead, and management repeatedly said the next release is only directional rather than definitive. The company is also relying on a novel mechanism with unproven human efficacy, and the endometriosis program is still in planning with initiation pushed to mid-2027. Investors also still lack placebo-adjusted clinical data from the ongoing hair-loss study.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.3%
- Shares Outstanding
- 172.75M
- Float Shares
- 149.12M
of shares held by institutions
208 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 25.74M | ▲ 331.98K |
| Blackrock, Inc. | 14.50M | ▲ 2.33M |
| Ark Investment Management LLC | 11.93M | ▼ 996.35K |
| State Street Corp | 8.46M | ▲ 363.28K |
| Vanguard Group Inc | 7.91M | ▲ 628.29K |
| Vanguard Capital Management LLC | 7.04M | ▲ 919.84K |
| Ameriprise Financial Inc | 6.99M | ▲ 3.81M |
| Redmile Group, LLC | 6.74M | ▼ 1.51M |
| Advanced Micro Devices Inc | 5.71M | 0 |
| Adage Capital Partners Gp, L.L.C. | 5.70M | ▲ 5.70M |
| Two Sigma Investments, LP | 5.49M | ▲ 2.59M |
| D. E. Shaw & Co., Inc. | 5.24M | ▲ 4.59M |
Held by 271 ETFs
Biggest fund positions in ABSI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 29, 26 | McClain Sean | other | 79,860 |
| Oct 12, 26 | McClain Sean | other | 23,293 |
| Oct 12, 26 | Bedrick Todd | other | 22,325 |
| Oct 12, 26 | Jonasson Zachariah | other | 387 |
| Aug 31, 26 | Jonasson Zachariah | other | 8,320 |
| Mar 3, 26 | Somaratne Ransi Mudalinayake | other | 650,000 |
| Aug 3, 26 | Somaratne Ransi Mudalinayake | other | 383,000 |
| Mar 3, 26 | Somaratne Ransi Mudalinayake | other | 0 |
| Jun 30, 26 | Szela Mary T | buy | 12,900 |
| Jun 24, 26 | McClain Sean | other | 59,896 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ABSI coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ABSI?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Absci Q3 Earnings Call Highlights
marketbeat.com · Nov 12
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 12
Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
globenewswire.com · Nov 12
Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline
globenewswire.com · Nov 12
Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
seekingalpha.com · Nov 11
Absci to Participate in Upcoming Investor Conferences
globenewswire.com · Oct 27
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
globenewswire.com · Oct 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
